Eylea keeps its lead in the retinal space as physicians remain hesitant on Roche's Susvimo — report

Roche trumpeted a “major advancement” in the retinal space with the approval of its eye drug Susvimo last October, touting it as a more manageable option for patients with wet age-related macular degeneration. However, safety concerns leave some physicians hesitant.